Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2013; 19(43): 7630-7638
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7630
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7630
Table 3 Food and Drug Administration approved medications for hepatitis B treatment
Generic name | Trade name | Company | Approved for HBV treatment |
Interferons | |||
Interferon α-2b, recombinant | Intron® A | Schering Corporation/ Merck and Co | 1992 |
Perinterferon α-2a | Pegasys® | Genentech/Roche group | 2005 |
Nucleosides/nucleotides | |||
Lamivudine1 | EPIVIR-HBV® | GlaxoSmithKline | 1998 |
Adefovir dipivoxil | HEPSERATM | Gilead Sciences | 2002 |
Entecavir | BARACLUDETM | Bristol-Myers Squibb | 2005 |
Telbivudine2 | TYZEKATM | Novartis | 2006 |
Tenofovir2 | Viread | Gilead Sciences | 2008 |
- Citation: Almashhrawi AA, Ahmed KT, Rahman RN, Hammoud GM, Ibdah JA. Liver diseases in pregnancy: Diseases not unique to pregnancy. World J Gastroenterol 2013; 19(43): 7630-7638
- URL: https://www.wjgnet.com/1007-9327/full/v19/i43/7630.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i43.7630